trending Market Intelligence /marketintelligence/en/news-insights/trending/3ee4rvzprjeq05tfj2o-6q2 content esgSubNav
In This List

OncoArendi Therapeutics plans IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


OncoArendi Therapeutics plans IPO

OncoArendi Therapeutics Sp. z o.o plans to launch an IPO in March or April, Reuters reported.

The Warsaw, Poland-based biopharmaceutical company will issue between 500,000 and 2 million new shares.

OncoArendi, which specializes in drugs for cancer and respiratory diseases, will offer about 90% of the shares to institutional investors and about 10% to retail investors.

Trigon Dom Maklerski, an investment banking firm, is acting as intermediary in the offer.